Novo Nordisk is under pressure from investors for more information about its next-generation obesity drug candidate CagriSema ...

Novo’s record profit from obesity drugs has given the Foundation a war chest to fund its philanthropic grants, although ...

In fact, Novo Nordisk recently reported positive results for one of its anti-obesity candidates that puts its current ...

Novo Nordisk is under investor pressure for transparency regarding their obesity drug CagriSema, after trial results disappointed. Patients report weight loss but side effects like nausea. Investors ...

Novo Nordisk A/S investors got a much-needed boost from last week’s trial results for an experimental weight-loss shot. But ...

Novo Nordisk A/S (NVO) stock saw a decline, ending the day at $84.45 which represents a decrease of $-0.89 or -1.04% from the prior close of $85.34. The stock opened at $84.87 and touched a low of $84 ...

The new treatment targets gut hormone GLP-1 but also mimics amylin, a hormone released by the pancreas that suppresses hunger ...

Expanded Ozempic approval in the U.S. could transform how doctors treat patients with chronic kidney disease, which involves ...

On Friday, however, Novo Nordisk announced top-line results in yet another trial. While the results don't initially sound as ...

The Novo Nordisk Foundation continues to prioritize its focus on non-communicable diseases despite a global health crisis prompted by the U.S. freeze on foreign aid. With substantial assets, the ...

Ozempic, or semaglutide, can now be used to reduce the risk of worsening kidney disease or kidney failure in adults with type ...

Here are some of the major companies whose stocks moved on the week’s news.